利奈唑胺治疗血小板减少合并革兰氏阳性球菌感染患者的疗效分析

摘要

Objective To observe and analyze the curative effect and safety of linezolid in the treatment of thrombocytopenia with Gram positive cocci infection (G+ ) .Methods By retrospective analysis ,82 cases of thrombocytopenia with Gram positive cocci in-fection patients were enrolled in this study .Linezolid was given at a dosage of 600 mg ,iv ,q12 h .The mean treatment period was 12 .58 ± 6 .52 days .The symptoms ,signs of change ,blood routine examination ,and pathogen culture were analyzed .Results 25 ca-ses appeared further platelet decrease after use of linezolid ,8 ± 4 d after medication .But most of the cases were Ⅲ thrombocytope-nia ,who only need to be closely observed or discontinuation of the treatment ,no need of transfusion of platelets .The majority of cases concentrated in the elderly (>60 years old) ,a total of 16 cases (64% ) .Conclusion Although platelet reversible decrease can be caused ,linezolid in the treatment of thrombocytopenia with Gram positive cocci infection patients is relative safe .%目的 观察并分析利奈唑胺治疗血小板减少合并革兰氏阳性球菌感染(G+)患者的疗效及安全性.方法 回顾性分析82例血小板减少合并革兰氏阳性球菌感染患者,静脉滴注利奈唑胺600mg,每12h1次,疗程为12.58±6.52d.观察患者症状、体征变化、血常规和病原体培养,分析其临床疗效及对血小板的影响.结果 82例患者中,出现进一步血小板下降的有25例,于用药后8±4 d发生.大部分为Ⅲ级以上血小板减少,仅需密切观察或停药处理,无需输注单采血小板等紧急处理,且血小板减少发生与用药前血小板计数基础值无明显相关.25例血小板减少患者集中于老年人(>60岁),共有16例(64%).结论 利奈唑胺对血小板减少合并革兰氏阳性球菌感染患者疗效显著,虽然可引起血小板可逆性下降,但用药相对安全.